

21
This United States patent application is a continuation-in-part of United States patent application No. 08/814,974, filed March 6, 1997, now United States patent 6,129,930, which is a continuation-in-part of United States patent application No. 08/368,378, filed January 14, 1995, now United States patent 6,080,428, which is a continuation-in-part of United States patent application No. 08/124,292, filed September 20, 1993, now abandoned.

REMARKS

Applicant has amended the specification to cross-reference prior applications from which the instant application claims priority under 35 U.S.C. § 120.

Respectfully submitted,

Date:

1/15/03



Karen J. Messick (Reg. No. 46,256)

Attorney for Applicant

c/o Kos Pharmaceuticals, Inc.

1001 Brickell Bay Drive

25th Floor

Miami, Florida 33131

Tel.: (305) 523-3643

Appendix of Amendments

IN THE SPECIFICATION

On page 1, under "Related Patent Applications":

[This application for U.S. patent is a U.S.C., Title 35 § 111(a) application, which is a continuation-in-part of U.S. Patent Application, Serial No. 08/814,974 filed March 6, 1997] This United States patent application is a continuation-in-part of United States patent application No. 08/814,974, filed March 6, 1997, now United States patent 6,129,930, which is a continuation-in-part of United States patent application No. 08/368,378, filed January 14, 1995, now United States patent 6,080,428, which is a continuation-in-part of United States patent application No. 08/124,292, filed September 20, 1993, now abandoned.